BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe ...
- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - “On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vertex Pharmaceuticals Incorporated is a $120bn market cap pharma giant with a successful CF franchise, growing revenues from $1bn in 2015 to $9.9bn in 2023. Vertex gained approval for its first ...
9d
CRISPR Therapeutics (CRSP) Gains Attention As CASGEVY Momentum Builds But Is The Valuation Too Rich
CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY ...
CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. In the European Union, CASGEVY is approved for patients 12 years of age and ...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions ...
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory ...
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results